Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an [...]
In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]
Memorial Sloan Kettering Cancer Center (MSKCC) recently announced results from a "basket study," an innovative clinical trial design that studies response to drugs based on specific mutations in patients' tumors rather than where the cancer originated.The [...]
A recent call to action from ASCO (American Society of Clinical Oncology) published in the Journal of Clinical Oncology recommends expanding clinical trials to include more older adults. Given that greater than 60% of cancers in [...]
This year, the Life Raft Group joined the Clinical Trials Transformation Initiative (CTTI) to help make clinical trials more efficient and productive and to help accelerate new treatments. CTTI is a consortium that brings [...]
A Phase II clinical trial comparing Imatinib alternated with Regorafenib to Imatinib alone is currently underway and recruiting in Australia. The trial, sponsored by the Australasian Gastro-Intestinal Trials Group, looks to examine the feasibility of [...]
Novartis Pharmaceuticals recently received FDA approval for panobinostat, a blood cancer drug that targets multiple myeloma. This was a surprising ruling, as it was a turnaround from last year’s Oncologic Drugs Advisory Committee’s 5-2 [...]
A recent report from the Institute of Medicine outlines the advantages of data sharing from clinical trials. The authors state that data sharing can lead to the discovery of new treatment modalities as well [...]
